159 related articles for article (PubMed ID: 38488402)
21. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
Falvella FS; Caporale M; Cheli S; Martinetti A; Berenato R; Maggi C; Niger M; Ricchini F; Bossi I; Di Bartolomeo M; Sottotetti E; Bernardi FF; de Braud F; Clementi E; Pietrantonio F
Int J Mol Sci; 2015 Apr; 16(4):8884-95. PubMed ID: 25906475
[TBL] [Abstract][Full Text] [Related]
22. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
24. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
26.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
28. Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
Wong BYL; Li Z; Raphael MJ; De Angelis C; Hwang DM; Fu L
J Appl Lab Med; 2024 Mar; 9(2):295-304. PubMed ID: 38084968
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
[TBL] [Abstract][Full Text] [Related]
30. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
[TBL] [Abstract][Full Text] [Related]
32. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
[TBL] [Abstract][Full Text] [Related]
33. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
34. DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol.
Hernández-Guío A; Bernabéu-Martínez MªÁ; Corno-Caparrós A; Aznar-Saliente MªT; Bonete-Sánchez M; Calleja-Hernández MÁ
Farm Hosp; 2021 Apr; 45(3):155-159. PubMed ID: 33941060
[TBL] [Abstract][Full Text] [Related]
35. Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.
Pinheiro M; Peixoto A; Rocha P; Santos C; Escudeiro C; Veiga I; Porto M; Guerra J; Barbosa A; Pinto C; Arinto P; Resende A; Teixeira MR
Pharmacogenet Genomics; 2023 Oct; 33(8):165-171. PubMed ID: 37611150
[TBL] [Abstract][Full Text] [Related]
36. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
37. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.
Li GY; Duan JF; Li WJ; Liu T
J Cancer Res Ther; 2016; 12(2):782-6. PubMed ID: 27461651
[TBL] [Abstract][Full Text] [Related]
38. Survival of Patients With Cancer With
Knikman JE; Wilting TA; Lopez-Yurda M; Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Nieboer P; Droogendijk HJ; Creemers GJ; Mandigers CMPW; Imholz ALT; Mathijssen RHJ; Portielje JEA; Valkenburg-van Iersel L; Vulink A; van der Poel MHW; Baars A; Swen JJ; Gelderblom H; Schellens JHM; Beijnen JH; Guchelaar HJ; Cats A
J Clin Oncol; 2023 Dec; 41(35):5411-5421. PubMed ID: 37639651
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Amstutz U; Farese S; Aebi S; Largiadèr CR
Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
[TBL] [Abstract][Full Text] [Related]
40. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
García-Alfonso P; Saiz-Rodríguez M; Mondéjar R; Salazar J; Páez D; Borobia AM; Safont MJ; García-García I; Colomer R; García-González X; Herrero MJ; López-Fernández LA; Abad-Santos F
Clin Transl Oncol; 2022 Mar; 24(3):483-494. PubMed ID: 34773566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
